Mohammad AskarPublic working copy · medical review pending

Glaucoma studies 2024–2025 · 128

Seven glaucoma studies: findings, uncertainty and decisions

Read the study design and patient selection before turning a result into a treatment rule. These 2024–2025 papers address medication, laser and filtering surgery.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Observational associations do not prove drug-induced inflammation, a harmful laser sequence or device superiority. Randomised findings still depend on the prespecified endpoint, selected population and follow-up.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01SOURCE: association is not drug causation

The SOURCE retrospective study compared adults newly starting prostaglandin analogues (PGA), beta-blockers, alpha agonists or topical carbonic anhydrase inhibitors across 10 health systems. Patients with documented previous uveitis were excluded from the main analysis; prescribing selection and coded diagnoses can still confound comparisons. 1 2

At 3 months, reported uveitis incidence was 0.32% with PGA,1.95% with beta-blockers,1.63% with alpha agonists and 1.68% with carbonic anhydrase inhibitors. Adjusted odds were about 5–6 times higher for the other classes than PGA; this does not mean that PGA prevents uveitis or that other drops caused each event. 2

The source itself differs: abstract 67517 patients versus 64517 in results/Table 1. In the latter, class shares were approximately 62%,17.5%,16.7% and 3.7%; mean onset 47 days with PGA and about 38–43 days otherwise, and anatomical categories 84.7% anterior,10.2% posterior,2.6% intermediate. Original rounded 62/17/18/4 and 80/15/5 are not exact source proportions. 1 2

At suspected medication-related uveitis, assess infection, disease history and each drug with an ophthalmologist. Supervised withdrawal or substitution may be appropriate with pressure cover; do not automatically stop and rechallenge every drug, particularly where inflammation is serious. 1 2

SOURCE: association is not drug causation
ParameterStudy and boundary
DesignRetrospective SOURCE database
PopulationNew adult drop users; prior uveitis excluded
Data10 health systems; 64517 main text/67517 abstract discrepancy
ComparisonPGA vs beta-blockers, alpha agonists, carbonic anhydrase inhibitors
OutcomeNew uveitis at 3 months; 6 months secondary
Source / limitChauhan 2025; confounding and source discrepancies

02ADHD medicines: separate angle closure and open-angle diagnoses

Darwich’s claims-based retrospective cohort with nested case-control analysis included 240257 new users of atomoxetine, amphetamines or methylphenidate, with 4 age-matched controls per case. Mean cohort age was 45 years; this is not a paediatric-only sample, and diagnostic codes do not replace angle examination. 1 3

Regular atomoxetine and amphetamine use was associated with angle-closure diagnoses, adjusted incidence-rate ratios 2.55 and 2.27, while methylphenidate was associated with open-angle glaucoma at 1.23. These relative associations neither quantify an individual’s absolute risk nor exclude angle closure with another agent or overturn a current product contraindication. 3

Original follow-up “up to 1 year” and US-use estimates 10% of children/4% of adults lack matched verification here. Discuss symptoms, anatomy, family history and other drugs; a pressure measurement alone cannot exclude an occludable angle, and medication changes should be coordinated with the prescriber. 1 3

ADHD medicines: separate angle closure and open-angle diagnoses
ParameterStudy and boundary
DesignRetrospective cohort with case-control analysis
Population240257 new ADHD-drug users
DataPharMetrics Plus (IQVIA, USA)
ComparisonAtomoxetine, methylphenidate, amphetamines; 4 controls per case
Outcome / timingAngle-closure/open-angle diagnoses; original 1 year limit unconfirmed
Source / limitDarwich 2024; association, not causation or label change

03GITS: read the primary endpoint before the subgroup

GITS randomised 242 patients with newly detected early or moderate untreated open-angle glaucoma at two Swedish centres to initial intensive medications plus 360°laser trabeculoplasty or stepwise monotherapy. The original 143 versus 155 eye counts need full-report reconciliation with the patient denominator and cannot replace randomised patient numbers. 1 4

At 5 years, median baseline pressure was 24 mmHg in both arms; follow-up pressure was 17 mmHg with monotherapy and 14 mmHg with intensive therapy, rather than 14 in both. Projected end-of-life VFI, the primary outcome, was 79.3% versus 87.1% (P=0.15); median annual losses 0.65 versus 0.25 percentage points (P=0.09). These comparisons were not statistically conclusive. 4

Progression events occurred in 21% versus 11% (P=0.03), with mostly mild adverse events in 25% versus 36%. Greater benefit above the median baseline around 24 mmHg came from post hoc analysis; it is a stratification hypothesis, not a universal 24 mmHg treatment threshold or proof of no benefit below it. Open-label treatment and projected lifetime outcomes limit interpretation. 4

GITS: read the primary endpoint before the subgroup
ParameterStudy and boundary
DesignOpen-label two-centre randomised trial
Population242 new early/moderate OAG patients, including PEX in original
ComparisonStepwise monotherapy vs intensive drugs+360°LTP; 143/155 eye counts pending
Follow-up5 years
OutcomeProjected end-of-life VFI primary; progression events secondary
Source / limitBengtsson 2024; primaryP=0.15, high-IOP subgroup post hoc

04After SLT: distinguish three active regimens from no treatment

Miranda’s prospective randomised trial included 134 eyes of 134 newly diagnosed POAG patients after primary SLT. It compared prednisolone acetate 1%, prednisolone acetate 0.12% and ketorolac 0.5%, not a placebo or untreated group; average follow-up was 287 days, so 12-month estimates are survival estimates rather than complete 1 year data for every eye. 1 5

The primary abstract reports 12-month success 83.7%,63.9% and 67.0% in that order (P=0.003), not 67.0% for prednisolone 1%. Overall final pressure was 14.39 mmHg from 19.57 mmHg; multivariable failure-related HR for the 1% group was 0.37 (95% CI0.15–0.91). Success definitions, censoring, dose schedule and steroid-response monitoring need the full report before applying the original one-week protocol. 1 5

After SLT: distinguish three active regimens from no treatment
ParameterStudy and boundary
DesignProspective randomised active-comparator trial
Population134 eyes/134 new POAG patients after primary SLT
ComparisonPrednisolone acetate 1%/0.12%; ketorolac 0.5%; original 360°/1 week details pending
Follow-up12 month survival estimate; mean 287 days
OutcomeSuccess 83.7/63.9/67.0%; original≥20%/no surgery-laser-drugs definition pending
Source / limitMiranda 2025; no untreated arm or universal steroid rule

05LTP before MIGS: identify confounding by treatment history

Mitchell used IRIS registry data 2013–2018 for angle-based MIGS with or without LTP in the preceding two years, with and without phacoemulsification. Propensity matching yielded 954 standalone eyes and 7522 combined eyes from 164965 procedures; medication data were unavailable. 1 6

Prior LTP was associated with further glaucoma surgery over 36 months; the abstract reports adjusted HR 1.53 (CI1.15–2.04). This is a relative reoperation hazard, not a 53 percentage-point risk increase. Severity, prior response and procedure selection can confound results; it does not prove that LTP damages later MIGS or justify universally skipping laser. 6

The original reports similar pressure reduction and higher reoperation risk with secondary glaucoma or very high baseline pressure; these details require matching full-report definitions. Reoperation is influenced by treatment thresholds and access, and is different from visual preservation or a complete medication-adjusted efficacy endpoint. 1 6

LTP before MIGS: identify confounding by treatment history
ParameterStudy and boundary
DesignRetrospective propensity-matched cohort
DataIRIS registry 2013–2018
ComparisonAngle-MIGS±phaco, with/without LTP in previous 2 years
Follow-up36 months
OutcomeSubsequent glaucoma surgery; adjustedHR 1.53, not absolute 53% increase
Source / limitMitchell 2024; no medication data, residual confounding

06Filtering devices: compare endpoints and baseline differences

Armstrong’s 6-centre retrospective nonrandomised series compared 577 eyes of 521 patients: 235 SIBS microshunts (PreserFlo),201 gelatin 45µm microstents (XEN) and 141 trabeculectomies with MMC, followed 12 months. SIBS eyes started with lower decision pressure; medication burden also differed, so adjustment cannot guarantee exchangeable groups. 1 7

For the main 17 mmHg criterion with at least 20% pressure reduction and limits on clinical hypotony, complete success was 68.8% with SIBS,46.2% with XEN and 58.0% with trabeculectomy; qualified success allowed medication and was 89.7%,70.1% and 83.6%. Original 65.3/40.1/52.1% at 6–14 mmHg and medians 12/14/13 mmHg need the matching secondary table and must not be substituted for the primary definition. 1 7

Complications were reported in 33.6%,42.8% and 56% respectively; definitions and intervention burden matter, not just a composite percentage. These findings support discussion, not universal device superiority; the original smaller Mainz comparison and claimed no-revision criterion remain unreconciled, and prospective independent comparisons are still needed. 1 7

Filtering devices: compare endpoints and baseline differences
ParameterStudy and boundary
DesignRetrospective nonrandomised 6-centre series
Population577 eyes/521 patients, primary standalone filtration with MMC
ComparisonPreserFlo 235, XEN 201, trabeculectomy 141
Follow-up12 months
OutcomePrimary 17 mmHg; secondary 14/21 mmHg; complete/qualified success, complications
Source / limitArmstrong 2025; different baselines, not causal device ranking

07Normal-tension glaucoma: a small uncontrolled series

Pillunat prospectively followed 42 White European POAG eyes after primary standalone PreserFlo: 29 high-pressure and 13 normal-pressure eyes, for one year. The median medicated mean 24 hour pressure in the normal-pressure group fell from 14.3 to 9.5 mmHg; 12.8 was the high-pressure group’s postoperative value, not the normal-pressure baseline. 1 8

At 1 year,92.5% of all eyes were medication-free; this overall denominator must not become an exact 92% estimate for the 13 normal-pressure eyes. Peak pressure and fluctuations decreased without statistically clear between-group differences; non-significance in a small series does not establish equivalent efficacy or safety. 8

Original targets 6–14/6–18 mmHg and an additional 30% normal-pressure reduction require their precise protocol definitions. Without randomisation or a trabeculectomy comparator, this is an early pressure-profile study, not proof of superior visual outcomes, no hypotony risk or a universal replacement for trabeculectomy. 1 8

Normal-tension glaucoma: a small uncontrolled series
ParameterStudy and boundary
DesignProspective uncontrolled single-centre case series
Population42 eyes: 29 high-pressure/13 normal-pressure POAG
InterventionPrimary standalone PreserFlo
Follow-up12 months
Outcome24 hour mean/peak/fluctuation; original 6–14/6–18 and≥30% definitions pending
Source / limitPillunat 2025; small normal-pressure sample, no trabeculectomy comparator
What are the main learning points?

Observational associations do not prove drug-induced inflammation, a harmful laser sequence or device superiority. Randomised findings still depend on the prespecified endpoint, selected population and follow-up.

When is assessment urgent?

Severe eye pain, redness, rapid visual loss, halos with headache or nausea, marked inflammation or suspected infection or neurological disease needs urgent assessment; do not stop glaucoma or ADHD medication on your own.

References and access status

  1. 1
    Immutable original export; seven-study2025lecture; Thomas Klink/DOG selection and approximately2,000-paper pool not independently verified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Chauhan et al.,2025 SOURCE

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.

  3. 3
    Darwich et al.,2024 ADHD medications

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.

  4. 4
    Bengtsson et al.,2024 GITS five years

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.

  5. 5
    Miranda et al.,2025 anti-inflammatory treatment after SLT

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.

  6. 6
    Mitchell et al.,2024 IRIS angle-MIGS after LTP

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.

  7. 7
    Armstrong et al.,2025 filtration comparison

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.

  8. 8
    Pillunat et al.,2025 PreserFlo HPG/NPG

    Parent read the complete primary abstract14November2026; SOURCE also selected results/Table1/Table2, ADHD indexed abstract with direct-page failure. Full reports, protocols, figures, secondary definitions, current local labels and source discrepancies remain unresolved.